Dashboard
1
Weak Long Term Fundamental Strength with a -16.54% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.93 times
- The company has been able to generate a Return on Equity (avg) of 3.30% signifying low profitability per unit of shareholders funds
2
Flat results in Jun 25
3
With ROE of -0.22%, it has a Very Expensive valuation with a 0.90 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.78%
0%
5.78%
6 Months
-0.56%
0%
-0.56%
1 Year
20.68%
0%
20.68%
2 Years
-40.27%
0%
-40.27%
3 Years
-36.48%
0%
-36.48%
4 Years
-77.24%
0%
-77.24%
5 Years
0%
0%
0.0%
medmix AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.15%
EBIT Growth (5y)
-16.54%
EBIT to Interest (avg)
4.02
Debt to EBITDA (avg)
1.93
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.62
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
5.43%
ROE (avg)
3.30%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.90
EV to EBIT
25.04
EV to EBITDA
7.11
EV to Capital Employed
0.92
EV to Sales
1.13
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.69%
ROE (Latest)
-0.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
486.60
477.10
1.99%
Operating Profit (PBDIT) excl Other Income
68.40
95.80
-28.60%
Interest
10.10
6.50
55.38%
Exceptional Items
-0.90
-8.40
89.29%
Consolidate Net Profit
0.70
11.60
-93.97%
Operating Profit Margin (Excl OI)
26.70%
96.80%
-7.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 1.99% vs 4.33% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -93.97% vs -73.64% in Dec 2022
About medmix AG 
medmix AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






